重组人血小板生成素治疗特发性和血液肿瘤化疗后血小板减少症的Ⅲ期临床研究

被引：14

作者：

陈协群

白庆咸

王一苇

张永清

张涛

王文清

董宝侠

乔庆大

张伟平

机构：

[1] 第四军医大学西京医院血液内科

来源：

第四军医大学学报 | 2004年 / 03期

关键词：

重组人血小板生成素; 急性白血病; 特发性血小板减少性紫癜; 非霍奇金淋巴瘤; 临床试验,Ⅲ期;

D O I：

暂无

中图分类号：

R558.2 [];

学科分类号：

摘要：

目的 :评估重组人血小板生成素 (rhTPO)治疗特发性和化疗后血小板减少的临床安全性和有效性 .方法 :①病例分组 :4例非霍奇金淋巴瘤 (NHL)患者入选随机交叉对照组 ,6例巩固治疗期急性白血病患者入选非随机自身对照组 ;难治性血小板减少性紫癜 (ITP)组入选 9例患者 ;②用药方法 :rhTPO 1 μg/kg ,皮下注射 ,每日 1次 ,疗程 1 4d ;③统计分析 :病例资料采用SPSS软件统计分析 .结果 :①血液肿瘤组 :试验组rhTPO治疗后血小板数均值、最高值皆大于对照 ,两周期血小板数用药前后差值相差显著 (P <0 .0 5 ) ,试验组血小板数低于 5 0× 1 0 9/L的持续日数、恢复至 75× 1 0 9/L和 1 0 0× 1 0 9/L以上需要日数均有不同程度缩短 ;②难治性ITP组 :rhTPO治疗后患者血小板数均值渐升高 ,至 1 7d达 1 0 1× 1 0 9/L ;用药前后血小板差值为 85 .6 7× 1 0 9/L ,其中血小板数达 30× 1 0 9/L ,5 0× 1 0 9/L及 1 0 0× 1 0 9/L所需日数分别为 9.89,1 3.5 6及 1 9.78d .结论 :rhTPO对部分难治性ITP及血液肿瘤化疗所致的血小板减少有一定疗效 ,且无明显毒副作用

引用

页码：261 / 264

页数：4

共 10 条

[1] Internalization of the thrombopoietin receptor is regulated by two cytoplasmic motifs. Dahlen DD,Broudy VC,Drachman JG. Blood . 2003
[2] Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Vadhan-Raj S. Seminars in Hematology . 2000
[3] Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Lok S,Kaushansky K,Holly RD,et al. Nature . 1994
[4] Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Bartley TD,Bogenberger J,Hunt P,et al. Cell . 1994
[5] Developmentofpancytope niawithneutralizingantibodiestothrombopoietinaftermulticyclechemotherapysupportedbymegakaryocytegrowthanddevelopmentfactor. BasserRL,O’’FlahertyE,GreenM ,etal. Blood . 2002
[6] A randomized, doubleblind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Archimbaud E,Ottmann OG,Yin JA,et al. Blood . 1999
[7] Thrombocytopenia caused by the development of antibodies to thrombopoietin. Li J,Yang C,Xia Y,et al. Blood . 2001
[8] Thrombopoietin therapy increases platelet yields in healthy platelet donors. Kuter DJ,Goodnough LT,Romo J,et al. Blood . 2001
[9] Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Vadhan-Raj S,Murray LJ,Bueso-Ramos C,et al. Annals of Internal Medicine . 1997
[10] Recombinanthumanthrombopoietinattenuatescarbo platin-inducedseverethrombocytopeniaandtheneedforplatelettransfusionsinpatientswithgynecologiccancer. Vadhan-RajS,VerschraegenCF,Bueso-RamosC,etal. Annals of Internal Medicine . 2000

← 1 →